Oxford-AstraZeneca vaccine submitted for EU regulation

The European Medicines Agency (EMA) has announced that the vaccine developed by AstraZeneca and the University of Oxford has been submitted for formal review for rollout across the European Union.

According to a statement released by the regulator on Tuesday, the two parties asked for the vaccine to be green-lit under an expedited process and could see approval by January 29 “provided that the data submitted on the quality, safety and efficacy of the vaccine are sufficiently robust and complete.”

The vaccine has already seen rollout in the UK, which has currently vaccinated over 2 million people.

Read more: AstraZeneca and Oxford Covid vaccine approved for UK rollout

The Pfizer vaccine, which has also seen rollout in the UK as well as the US, has already been given the green light as has the vaccine developed by American pharmaceutical company Moderna.

The EU has been struggling to rollout vaccines to inoculate people across the entire bloc, but many of the leading vaccine companies have pumped up production for the potential of billions of doses by the end of the year.

The Oxford-AstraZenca vaccine is expected to be a key vaccine for many nations owing to its low-cost and ease of storage, requiring more acceptable temperatures for storage when compared to the far colder temperatures the Pfizer vaccine requires.

AstraZeneca plans to have 3 billion doses ready by the end of the year, and the vaccine will be made available for $2.50 (€3.04) per dose.

Back to Homepage

Back to Healthcare